Quick Answer
Serina Therapeutics, Inc. reported Gross Profit of $102.0 thousand for the year ending 2023.
- Serina Therapeutics, Inc. showed an increase of +385.7% in Gross Profit from 2022 to 2023.
- This data is from Serina Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 22, 2024.
- XBRL data for this metric is available from 2017 to 2023 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2018: $130.0 thousand | Q2 2018: $385.0 thousand | Q3 2018: $384.0 thousand | Q1 2019: $325.0 thousand | Q2 2019: $327.0 thousand | Q3 2019: $362.0 thousand | Q1 2020: $88.0 thousand | Q2 2020: $42.0 thousand | Q3 2020: $52.0 thousand | Q1 2021: $53.0 thousand | Q2 2021: $24.0 thousand | Q3 2021: $22.0 thousand | Q1 2022: $4.0 thousand | Q2 2022: $6.0 thousand | Q3 2022: $4.0 thousand | Q1 2023: $9.0 thousand | Q2 2023: $4.0 thousand | Q3 2023: $34.0 thousand.
- Over the full 7 years of available data (2017 to 2023), Serina Therapeutics, Inc.'s Gross Profit has declined by 91.7%.
- Historical annual values: Fiscal year 2023: $102.0 thousand | Fiscal year 2022: $21.0 thousand | Fiscal year 2021: $125.0 thousand | Fiscal year 2020: $335.0 thousand | Fiscal year 2019: $1.48 million | Fiscal year 2018: $1.03 million | Fiscal year 2017: $1.24 million.
- Data sourced from SEC EDGAR public filings as of August 4, 2026.
Last verified: